Regal Investment Advisors LLC increased its holdings in CVS Health Corp (NYSE:CVS) by 23.0% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 3,529 shares of the pharmacy operator’s stock after purchasing an additional 660 shares during the period. Regal Investment Advisors LLC’s holdings in CVS Health were worth $231,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in CVS Health by 1.7% in the 3rd quarter. Vanguard Group Inc. now owns 84,873,814 shares of the pharmacy operator’s stock valued at $6,681,267,000 after purchasing an additional 1,445,887 shares during the period. Vanguard Group Inc boosted its holdings in CVS Health by 1.7% in the 3rd quarter. Vanguard Group Inc now owns 84,873,814 shares of the pharmacy operator’s stock valued at $6,681,267,000 after purchasing an additional 1,445,887 shares during the period. BlackRock Inc. boosted its holdings in CVS Health by 2.8% in the 3rd quarter. BlackRock Inc. now owns 76,197,017 shares of the pharmacy operator’s stock valued at $5,998,231,000 after purchasing an additional 2,061,915 shares during the period. FMR LLC boosted its holdings in CVS Health by 4.3% in the 3rd quarter. FMR LLC now owns 30,069,260 shares of the pharmacy operator’s stock valued at $2,367,052,000 after purchasing an additional 1,250,473 shares during the period. Finally, Dodge & Cox bought a new position in CVS Health in the 3rd quarter valued at $1,190,694,000. 90.60% of the stock is owned by institutional investors.
CVS has been the subject of several analyst reports. ValuEngine raised shares of CVS Health from a “sell” rating to a “hold” rating in a report on Tuesday, November 6th. Royal Bank of Canada set a $100.00 price target on shares of CVS Health and gave the company a “buy” rating in a report on Wednesday, November 7th. Morgan Stanley set a $100.00 price target on shares of CVS Health and gave the company a “buy” rating in a report on Wednesday, November 7th. Leerink Swann raised their price target on shares of CVS Health from $85.00 to $95.00 and gave the company a “positive” rating in a report on Thursday, November 8th. Finally, Loop Capital set a $80.00 price target on shares of CVS Health and gave the company a “hold” rating in a report on Friday, November 9th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and fourteen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $85.50.
In other news, COO Jonathan C. Roberts sold 77,639 shares of CVS Health stock in a transaction on Friday, February 1st. The shares were sold at an average price of $64.54, for a total transaction of $5,010,821.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Larry J. Merlo sold 166,368 shares of CVS Health stock in a transaction on Tuesday, January 8th. The stock was sold at an average price of $69.04, for a total transaction of $11,486,046.72. Following the sale, the insider now directly owns 496,577 shares of the company’s stock, valued at $34,283,676.08. The disclosure for this sale can be found here. Insiders have sold a total of 410,375 shares of company stock valued at $27,229,267 over the last ninety days. 0.53% of the stock is currently owned by insiders.
NYSE CVS opened at $57.83 on Friday. CVS Health Corp has a 52-week low of $57.56 and a 52-week high of $82.15. The company has a quick ratio of 1.94, a current ratio of 1.03 and a debt-to-equity ratio of 1.22. The firm has a market cap of $63.11 billion, a PE ratio of 8.17, a P/E/G ratio of 0.90 and a beta of 1.03.
CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, February 20th. The pharmacy operator reported $2.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.07 by $0.07. CVS Health had a negative net margin of 0.31% and a positive return on equity of 17.49%. The company had revenue of $54.42 billion during the quarter, compared to the consensus estimate of $53.78 billion. During the same period in the previous year, the firm posted $1.92 EPS. The firm’s revenue was up 12.5% compared to the same quarter last year. On average, equities analysts expect that CVS Health Corp will post 6.81 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Monday, February 4th. Stockholders of record on Friday, January 25th were issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 3.46%. The ex-dividend date of this dividend was Thursday, January 24th. CVS Health’s dividend payout ratio is currently 28.25%.
CVS Health Profile
CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.
See Also: What is a Roth IRA?
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.